Latest Breaking News On - European medicines agency neurosense opens eu office - Page 1 : comparemela.com

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the.

United kingdomPrnewswire neurosense therapeutics ltdCompany phaseDrug administrationExchange commissionEuropean medicines agency neurosense opens eu officeEuropean medicines agencyNeurosense therapeutics ltdSense therapeuticsAmyotrophic lateral sclerosisCompleted double blind segmentInvestigator initiated trialSlow vital capacityPrimec aheadPivotal phaseSponsored study demonstrated primec